Search Results

Feature | October 2019

What Does Efficacy Cost? Evidence for Relative Cost-Effectiveness of Biologic Therapies for Psoriasis

Despite high costs, evidence suggests that biologics are cost-effective options for moderate to severe psoriasis because of their efficacy.

Jerry Bagel, MD, FAAD; Ted Lain, MD, MBA; and Lawrence J. Green, MD

Clinical Focus | August 2019

Parting Words from Jerry Bagel, MD

The psoriasis treatment landscape has changed dramatically during this editor’s tenure.

Jerry Bagel, MD, FAAD

Clinical Focus | May 2019

A Closer Look at Skyrizi

The newest IL-23 blocker for psoriasis may prove to be a blockbuster, according to analysts.

Jerry Bagel, MD, FAAD

Clinical Focus | February 2019

Biologics in Psoriasis: The Next Generation

Get familiar with the IL-23 monoclonal antibodies.

Jerry Bagel, MD, FAAD

Clinical Focus | January 2019

What's on the Horizon for Common Skin Diseases?

Experts share their psoriasis, acne, and AD wish lists for 2019.

Jerry Bagel, MD, FAAD; Peter A. Lio, MD; and Joshua Zeichner, MD

Clinical Focus | October 2018

First, Do No Harm

Weighing the data on Cimzia during pregnancy and lactation.

Jerry Bagel, MD, FAAD

Clinical Focus | July 2018

New Therapeutic Options for the Treatment of Psoriatic Arthritis: IL-17 Blockers

Are TNF inhibitors still the gold standard for PsA?

Jerry Bagel, MD, FAAD

Clinical Focus | February 2018

It's Time to Get Serious About Scalp Psoriasis Treatment

Largely due to adherence issues, topical treatments don't work for many scalp psoriasis patients.

Jerry Bagel, MD, FAAD

Clinical Foucs | August 2017

What Is Really Going On In Psoriatic Skin?

Take a walk through the pathogenesis of psoriasis to understand how new and emerging therapies may offer benefit.

Jerry Bagel, MD, FAAD

Clinical Focus | July 2017

Psoriasis Wish List

Clinical thought leaders share what they hope for to improve treatment in the future.

With Jerry Bagel, MD; Seemal R. Desai, MD, FAAD; Adam Friedman, MD, FAAD; and Gary Goldenberg, MD

Clinical Foucs | April 2017

Are We All Clear?

Understanding the safety of biologics for psoriasis in real-world settings.

Jerry Bagel, MD

Clinical Focus | December 2016

Reflecting on 2016: Big Stories in Acne, Psoriasis and AD

Columnists take stock of advancements over the last 12 months, with a focus on clinical implications.

Joshua Zeichner, MD, Jerry Bagel, MD, and Peter Lio, MD

July 2016

Physician Spotlight: Jerry Bagel, MD, FAAD

Director, Psoriasis Treatment Center of Central New Jersey

December 2014

New Oral Agent May Shift Psoriasis Treatment Landscape

A notable approval in 2014, apremilast may play an important role in bridging a wide gap in the care of moderate to severe psoriasis.

Jerry Bagel

Clinical Focus: Psoriasis | October 2014

Weight Loss in the Treatment of Psoriasis

Lifestyle changes such as better diet and exercise habits have been shown to have positive treatment benefits on psoriasis.

Jerry Bagel, MD

September 2014

Biologics: Understanding Safety and Access

Jerry Bagel, MD

May 2014

Emerging Therapies in the Evolving Biologic Platform for Psoriasis Treatment

Jerry Bagel, MD

Clinical Focus | November 2013

Weighing the Prospects of Biosimilars

If they are found to be comparable to the “originators,” biosimilar agents may offer patients significant therapeutic benefits as well as cost efficiency.

Jerry Bagel, MD

Cliniacal Focus: Psoriasis | July 2013

Psoriasis and the Metabolic Syndrome

Growing data support the notion that TNF inhibitors may decrease various risk factors for the metabolic syndrome.

Jerry Bagel, MD